| Legal Status: | Investigational |
| Cas Number: | 1401436-95-0 |
| Pubchem: | 66571003 |
| Drugbank: | DB18245 |
| Chemspiderid: | 57617733 |
| Unii: | 8Z28M5SX0X |
| Kegg: | D12009 |
| Chembl: | 4650214 |
| Iupac Name: | 4-[2-(difluoromethyl)benzimidazol-1-yl]-N-[2-methyl-1-[2-(1-methylpiperidin-4-yl)phenyl]propan-2-yl]-6-morpholin-4-yl-1,3,5-triazin-2-amine |
| C: | 31 |
| H: | 38 |
| F: | 2 |
| N: | 8 |
| O: | 1 |
| Smiles: | CC(C)(CC1=CC=CC=C1C2CCN(CC2)C)NC3=NC(=NC(=N3)N4CCOCC4)N5C6=CC=CC=C6N=C5C(F)F |
| Stdinchi: | 1S/C31H38F2N8O/c1-31(2,20-22-8-4-5-9-23(22)21-12-14-39(3)15-13-21)38-28-35-29(40-16-18-42-19-17-40)37-30(36-28)41-25-11-7-6-10-24(25)34-27(41)26(32)33/h4-11,21,26H,12-20H2,1-3H3,(H,35,36,37,38) |
| Stdinchikey: | WPFUFWIHMYZXSF-UHFFFAOYSA-N |
Zandelisib is an investigational new drug that is being evaluated to treat follicular lymphoma.[1] It is a phosphatidylinositol 3 kinase delta inhibitor.[2]